-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NE-3107 in Mild Cognitive Impairment
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NE-3107 in Mild Cognitive Impairment report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NE-3107 in Mild Cognitive Impairment Drug Details: NE-3107 (Triolex, HE3286) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NBI-1065846 in Cognitive Impairment Associated With Schizophrenia (CIAS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NBI-1065846 in Cognitive Impairment Associated With Schizophrenia (CIAS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NBI-1065846 in Cognitive Impairment Associated With Schizophrenia (CIAS)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KYN-5356 in Cognitive Impairment Associated With Schizophrenia (CIAS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KYN-5356 in Cognitive Impairment Associated With Schizophrenia (CIAS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KYN-5356 in Cognitive Impairment Associated With Schizophrenia (CIAS)...
-
Product Insights
NewCognitive Impairment – Drugs In Development, 2024
Empower your strategies with our Cognitive Impairment – Drugs In Development, 2024 report and make more profitable business decisions. Cognitive impairment is a condition characterized by a decline in cognitive functions, such as memory, attention, and problem-solving skills. It can range from mild to severe and may result from various causes, including aging, neurodegenerative diseases (like Alzheimer's), vascular disorders, traumatic brain injuries, infections, medication side effects, mental health issues, nutritional deficiencies, or environmental factors. Symptoms can include memory loss, confusion, difficulty...
-
Product Insights
NewMild Cognitive Impairment – Drugs In Development, 2024
Empower your strategies with our Mild Cognitive Impairment – Drugs In Development, 2024 report and make more profitable business decisions. Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety, and apathy. Risk factors include diabetes, high blood pressure, depression, smoking, and elevated cholesterol. The Mild...
-
Product Insights
NewCognitive Impairment Associated With Schizophrenia (CIAS) – Drugs In Development, 2024
Empower your strategies with our Cognitive Impairment Associated With Schizophrenia (CIAS) – Drugs In Development, 2024 report and make more profitable business decisions. Cognitive functioning is moderately to severely impaired in patients with schizophrenia. Symptoms of cognitive impariment associated with schizophrenia (CIAS) include poor executive functioning, inability to sustain attention, and problems with working memory. Predisposing factors include family history, age, and autoimmune diseases. Treatment includes antipsychotic medications. The Cognitive Impairment Associated With Schizophrenia (CIAS) drugs in development market research report...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dalzanemdor in Dementia Associated With Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dalzanemdor in Dementia Associated With Alzheimer's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dalzanemdor in Dementia Associated With Alzheimer's Disease Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UE-2343 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UE-2343 in Alzheimer's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. UE-2343 in Alzheimer's Disease Drug Details: UE-2343 (Xanamem) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dalzanemdor in Huntington Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dalzanemdor in Huntington Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dalzanemdor in Huntington Disease Drug Details: Dalzanemdor (SAGE-718) is under development...